Scotland-based Kynos Therapeutics has launched a first-in-human Phase I trial of its kynurenine 3-monooxygenase (KMO) inhibitor KNS366. The study aims to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of KNS366 in healthy adult participants. The study is being conducted at a single site in the UK. Full results from the […]
